LGR5 Antibodies Targeting Amino Acids 22–37 for Expression-Level Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of robust, validated antibody-based treatments targeting LGR5 for the treatment of cancer and inflammatory diseases, as well as a need for specific antibodies that can distinguish cells with high levels of LGR5 expression from those with lower expression levels.
Innovation Solution
Development of antibodies that bind specifically to the epitope within amino acids 22-37 of LGR5, demonstrating high affinity and rapid uptake by LGR5-expressing cancer cells, which can be used as therapeutic agents or research tools.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antibody treatments are used, then treatment options are available, but they lack robust validation and specificity for distinguishing high LGR5 expression cells from low expression cells
Solution Approach 1:
The patent applies parameter changes by generating antibodies with different binding specificities against LGR5. Specifically, the invention creates antibodies that bind to distinct epitopes on the LGR5 protein, enabling differentiation between cells with high and low LGR5 expression. This involves modifying the antibody structure and binding characteristics to achieve the desired specificity and validation robustness.
2Reliability
If antibodies with high affinity bind to LGR5, then therapeutic effectiveness is improved, but rapid uptake by cancer cells may reduce availability for therapeutic action
Solution Approach 1:
The patent applies parameter changes by optimizing the antibody's binding kinetics and affinity parameters. The invention generates antibodies with specific binding characteristics that balance high affinity for LGR5 with appropriate uptake rates. This involves adjusting the antibody structure, Fc region properties, and binding epitopes to achieve the optimal balance between binding strength and cellular uptake.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies effectively target and distinguish LGR5-expressing cancer cells, providing a basis for therapeutic interventions and diagnostic tools, with applications in treating various cancer types and inflammatory diseases.
Implementation Method 1
antibodies which bind to human and cynomolgus (cyno) LGR5, wherein the antibody binds an epitope within amino acids 22-37 of LGR5
Implementation Method 2
the antibody binds an epitope within amino acids 22-37 of LGR5... demonstrating high affinity and rapid uptake by LGR5-expressing cancer cells
Data Source
AI summary
LGR5 binding agents, in particular antibodies or fragments thereof which bind to human LGR5, and the use of such binding agents in the treatment of disease, such as cancer and inflammatory disease, and the detection of LGR5.